Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to...
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrillation (AF), an irregular heartbeat that can increase the likelihood of stroke, was...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Montreal Heart Institute (MHI) presented new data that shows catheter ablation as...
The AHA 2020 late-breaking SAMSON Trial found side effects reported from statins are real, but appear due to the psychological rather than the pharmacological effects of the cholesterol lowering drugs. #AHA20 #AHA2020

The AHA 2020 late-breaking SAMSON Trial found side effects reported from statins are real, but appear due to the psychological rather than the pharmacological effects of the cholesterol  lowering drugs.

News | Pharmaceuticals | November 16, 2020
November 16, 2020 — Among patients who stopped taking their cholesterol-lowering statin medication due to side effects...
New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender. Getty Images.

Getty Images

News | Pharmaceuticals | November 16, 2020
November 16, 2020 — Novartis announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11...
The FDA-Cleared XO Score is different. XO Score technology allows users to convert basic angioplasty balloons in the hospital's existing inventory into sophisticated scoring, cutting, and infusion/delivery devices. 

The FDA-Cleared XO Score is different. XO Score technology allows users to convert basic angioplasty balloons in the hospital's existing inventory into sophisticated scoring, cutting, and infusion/delivery devices. 

News | Peripheral Artery Disease (PAD) | November 13, 2020
November 13, 2020 — The new U.S. Food and Drug Administration (FDA) cleared XO Score system was successfully used to...
Videos | Coronavirus (COVID-19) | November 12, 2020
Eric Gantwerker, M.D., vice president and medical director at clinical video game simulator company Level Ex, and...
Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS.

Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS. 

News | Artificial Intelligence | November 12, 2020
November 12, 2020 – Konica Minolta Healthcare Americas Inc. and DiA Imaging Analysis Ltd. jointly announce the expanded...
Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days.

Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days. 

News | Hemodynamic Support Devices | November 12, 2020
November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE (...
Videos | Coronavirus (COVID-19) | November 10, 2020
Keith Ellis, M.D., is the director of cardiovascular services and the director of the Chest Pain Center at Houston...
The impact of COVID-19 on the heart and cardiovascular system is being evaluated in a new clinic for post-COVID patients to monitor and manage their cardiac recovery.
News | Coronavirus (COVID-19) | November 10, 2020
November 10, 2020 — The Smidt Heart Institute at Cedars-Sinai Hospital in Los Angeles has established a specialized...
NIH trial, the Outcomes Related to COVID-19 treated with Hydroxychloroquine among Inpatients with symptomatic Disease (ORCHID), showed no difference in deaths between placebo and hydroxychloroquine. Getty Images
News | Coronavirus (COVID-19) | November 09, 2020 | Dave Fornell, Editor
November 9, 2020 — A National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of...
SCCT Releases New Guidelines for Cardiology and Radiology Trainees in Cardiovascular CT
News | CT Angiography (CTA) | November 09, 2020
November 6, 2020 — The Society of Cardiovascular Computed Tomography (SCCT) has released a new training guideline,...
An example of radiation dose tracking software from Imalogix showing data on cath lab angiography cases at RSNA 2019. Photo by Dave Fornell

An example of radiation dose tracking software from Imalogix showing data on cath lab angiography cases. Photo by Dave Fornell

Feature | Radiation Dose Management | November 04, 2020 | Dave Fornell, Editor
More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that...
The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).  
News | Drug-Eluting Balloons | November 03, 2020
November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated...